State of Wisconsin Investment Board acquired a new stake in shares of Athersys, Inc. (NASDAQ:ATHX) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 75,000 shares of the biopharmaceutical company’s stock, valued at approximately $113,000. State of Wisconsin Investment Board owned approximately 0.07% of Athersys at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ATHX. Vanguard Group Inc. lifted its holdings in Athersys by 19.5% during the 1st quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock valued at $6,668,000 after buying an additional 637,322 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Athersys by 35.2% during the 1st quarter. Geode Capital Management LLC now owns 756,004 shares of the biopharmaceutical company’s stock valued at $1,292,000 after buying an additional 196,981 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Athersys by 327.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 240,056 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 183,867 shares in the last quarter. FNY Partners Fund LP bought a new stake in Athersys during the 1st quarter valued at about $206,000. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Athersys by 99.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 240,200 shares of the biopharmaceutical company’s stock valued at $363,000 after buying an additional 120,000 shares in the last quarter. Institutional investors own 19.08% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/17/75000-shares-in-athersys-inc-athx-purchased-by-state-of-wisconsin-investment-board.html.

ATHX has been the subject of a number of research analyst reports. Maxim Group set a $12.00 price objective on shares of Athersys and gave the company a “buy” rating in a report on Monday, August 7th. Zacks Investment Research raised shares of Athersys from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Monday, August 14th. Finally, ValuEngine raised shares of Athersys from a “sell” rating to a “hold” rating in a research report on Friday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Athersys presently has a consensus rating of “Buy” and a consensus target price of $7.08.

Athersys, Inc. (NASDAQ ATHX) opened at 2.22 on Friday. The stock’s market cap is $252.88 million. Athersys, Inc. has a 52-week low of $1.02 and a 52-week high of $2.30. The firm’s 50-day moving average is $1.72 and its 200-day moving average is $1.52.

Athersys (NASDAQ:ATHX) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.06). Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. The company had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $0.96 million. During the same quarter in the prior year, the company posted ($0.08) earnings per share. Athersys’s revenue for the quarter was up 12.4% compared to the same quarter last year. Equities research analysts predict that Athersys, Inc. will post ($0.24) earnings per share for the current year.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Stock Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related stocks with our FREE daily email newsletter.